E&C Committee Reviews 340B Drug Pricing Program, Offers Recommendations

Drug Industry Daily
A A
The House Energy and Commerce Committee released a review of the 340B drug discount pricing program, identifying weaknesses in oversight and administration, among other issues, and offering recommendations to resolve them.

To View This Article:

Login

Subscribe To Drug Industry Daily